Morgans has run the rule over three of the most widely held shares on the ASX 200. The broker has issued updated ratings and price targets on Cochlear Limited, South32 Limited, and Westpac Banking Corporation following recent company updates.
Figure 1: ASX signage representing the Australian stock market backdrop [Courtesy: Bez kabli]
The verdicts are mixed. Each Company sits at a different point in its cycle, and the broker’s views reflect that divergence clearly.
1. Cochlear Limited (ASX: COH)
Cochlear Limited delivered a first-half FY2026 result that came in below market expectations. Revenue, margins, and profit were all affected by longer-than-anticipated contracting for the newly launched Nucleus Nexa system.
Morgans noted that demand for Nucleus Nexa is building, but the pace of adoption has not been fast enough to offset near-term headwinds. The broker has maintained a cautious stance on the stock.
Figure 2: Cochlear Limited logo [Courtesy: Wikimedia Commons]
What Morgans Said on the Cochlear Share Price Forecast
Morgans moved to a Hold rating on Cochlear Limited, lowering its Cochlear share price forecast to A$214.93. The broker noted that while management maintained FY26 guidance, it is now targeting the lower end of the range.
In its assessment, Morgans stated: “While Nexa adoption accelerated late in the half and management maintained FY26 guidance, but now is targeting the lower end of the range, it increases reliance on a strong 2H recovery, which appears optimistic, especially in light of flat GM and FX headwinds.”
Cochlear Share Price Forecast Sits Well Above Current Levels
The Cochlear share price forecast of A$214.93 represents meaningful upside from the current trading price. Morgans acknowledged the share price weakness as the basis for moving to Hold rather than a more cautious rating.
Flat gross margins and foreign exchange headwinds remain the key risks to monitor through the second half of FY2026.
2. South32 Limited (ASX: S32)
South32 Limited delivered a first-half FY2026 result that outperformed expectations. Consistent production and higher base and precious metals prices drove a bumper EBITDA result comfortably ahead of consensus.
The Company also delivered a 15% interim dividend beat alongside an upsized capital management programme, adding an extra US$100 million beyond initial plans. Despite the strong result, Morgans revised its South32 ASX rating.
Figure 3: South32 Limited logo [Courtesy: Wikimedia Commons]
Morgans Lowers the South32 ASX Rating From Buy to Accumulate
The updated South32 ASX rating is now Accumulate, stepped down from Buy. Morgans maintained its unchanged price target of A$5.00. The broker recommended patience when adding to positions following the recent share price surge.
Morgans stated: “Bumper 1H26 EBITDA comfortably ahead of consensus and close to our estimate, riding consistent production and higher base and precious metals. 15% interim dividend beat and upsized capital management of an extra US$100 million.”
One Near-Term Risk to Watch at Hermosa
While the South32 ASX rating remains positive overall, Morgans flagged the Hermosa budget increase as a short-term risk to monitor in the second half. Guidance was otherwise unchanged, with minor tweaks to Brazil Aluminium output and capital expenditure timing.
The current South32 share price of A$4.42 compares to the broker’s A$5.00 price target, indicating upside remains on the table for patient investors.
3. Westpac Banking Corporation (ASX: WBC)
Westpac Banking Corporation released its first-quarter FY2026 update, which Morgans described as largely stable compared to the second-half FY2025 quarterly average. The result was better than first-half FY2026 expectations when normalised for restructuring charges.
Despite the improved outlook, Morgans upgraded Westpac shares only to a Trim rating, which sits between Sell and Hold. The broker lifted its price target to A$35.12 per share.
Figure 4: Westpac Banking Corporation logo [Courtesy: CEO Water Mandate]
Why Morgans Remains Cautious on Westpac Shares
The Trim rating on Westpac shares reflects the fact that the current share price of A$39.85 sits materially above the broker’s A$35.12 price target. Morgans cited a still-negative potential total shareholder return as the reason for caution despite upgrading its view.
Morgans stated: “There is no change to FY26F EPS but there are 5 to 8% upgrades to FY27-28F. Target price lifts to A$35.12 per share. We upgrade to TRIM given the improved, but still negative, potential TSR.”
Westpac Shares: What Changed in the Broker’s Estimates
Morgans adopted a more bullish loan growth and impairments outlook than previously assumed, alongside slightly more conservative cost assumptions. While full-year FY2026 earnings per share estimates remain unchanged, FY2027 and FY2028 forecasts were upgraded by 5 to 8%.
The Westpac shares Trim rating signals that while the business is improving, the current valuation limits near-term upside in the broker’s view.
Share Price Summary
Industry Outlook
The ASX 200 continues to draw attention from domestic and institutional investors seeking exposure across healthcare, resources, and financials. Hearing implant technology, base metals, and banking remain three of the most actively covered sectors by Australian equity brokers.
Broker rating cycles on large-cap ASX names often reflect short-term result volatility rather than structural shifts. Investors tracking the Cochlear share price forecast, South32 ASX rating, and Westpac shares positioning will find the next set of quarterly and half-year updates critical in determining whether current broker stances are revised.
Future Direction and Impact on ASX Investors
For investors following the Cochlear share price forecast, the key catalyst ahead is the second-half FY2026 result and whether Nucleus Nexa adoption delivers the recovery management is targeting. Flat margins and currency headwinds will remain in focus.
On the South32 ASX rating, the Hermosa budget update in the second half is the most immediate variable. For those holding Westpac shares, the gap between the current price and the broker’s A$35.12 target is a signal worth watching as loan growth and cost trends develop through FY2026.
Frequently Asked Questions
Q1. What is the current Cochlear share price forecast from Morgans?
Ans. Morgans has set a Cochlear share price forecast of A$214.93, with a Hold rating as of 6 Apr 2026.
Q2. What is the South32 ASX rating from Morgans?
Ans. Morgans revised its South32 ASX rating to Accumulate from Buy, maintaining an unchanged price target of A$5.00.
Q3. What does the Trim rating on Westpac shares mean?
Ans. A Trim rating from Morgans sits between Sell and Hold. It indicates the broker sees limited upside or negative total shareholder return at the current Westpac share price of A$39.85.
Q4. Why did Morgans lower the South32 ASX rating despite a strong result?
Ans. The downgrade from Buy to Accumulate reflects valuation concerns following the recent share price surge, not any weakness in the Company’s underlying performance.
Q5. Is the Cochlear share price forecast above or below the current price?
Ans. The Cochlear share price forecast of A$214.93 is well above the current trading price of A$172.36, indicating potential upside even on a Hold rating.
Disclaimer
This article is intended for informational purposes only and does not constitute financial or investment advice. All content is based on broker research published on 6 Apr 2026 and supplementary publicly available sources. Share price, market capitalisation, and EPS data reflect figures available at the time of publication. Investing in securities involves risk. Readers should conduct their own research and seek independent financial advice before making any investment decisions. Colitco does not hold any position in the companies or organisations mentioned.
Sources
https://www.fool.com.au/2026/04/06/buy-hold-sell-cochlear-south32-and-westpac-shares/
https://www.asx.com.au/markets/company/COH
https://www.asx.com.au/markets/company/S32
https://www.asx.com.au/markets/company/WBC
Last modified: April 7, 2026
